Tofersen has been tested vs. placebo in a phase III randomized, double-blind, placebo-controlled trial (VALOR NCT02623699) (15) and is currently under investigation in an open-label extension (OLE) study (NCT03070119) in SOD1-ALS patients. The gene discussed is SOD1; the disease is amyotrophic lateral sclerosis.